Q.01

What manufacturing rules does the FDA set for finished medicines?

FDA's manufacturing rules for finished medicines are the current good manufacturing practice (CGMP) regulations in 21 CFR Part 211, "Current Good Manufacturing Practice for Finished Pharmaceuticals". 21 CFR Part 210 sits above it and sets the general provisions. Part 211 states that it contains "the minimum current good manufacturing practice for preparation of drug products … for administration to humans or animals". Positron emission tomography (PET) drugs and medical gases are excluded (211.1(a)). Under 210.1(b), failure to comply "shall render such drug to be adulterated under section 501(a)(2)(B) of the act", and both the drug and the person responsible "shall be subject to regulatory action".

Approach: I read the current text of 21 CFR Parts 210 and 211 on the official eCFR. My regulatory dataset for these parts did not respond this time, so everything below comes from the eCFR text.

Scope and how Part 211 fits with other rules

  • Drug product means "a finished dosage form, for example, tablet, capsule, solution, etc." It includes placebos (210.3(b)(4)).
  • Other CGMP parts add to Part 211. The rules for biologics (Parts 600-680) and for human cells and tissues regulated as drugs (Part 1271) "supplement and do not supersede" Part 211. Where they conflict, the more specific rule wins (211.1(b), 210.2(a)).
  • Partial operations: a firm doing only some regulated operations "need only comply with those regulations applicable to the operations in which the person is engaged" (210.2(b)).
  • Phase 1 investigational drugs are exempt from Part 211. The exemption ends once the drug is made available for a phase 2 or 3 study or is lawfully marketed (210.2(c)).
  • OTC drugs that are also foods: Part 211 is not enforced for them pending a proposed exemption. The food CGMP rules in Parts 110 and 117 apply instead (211.1(c)).

What Part 211 requires, subpart by subpart

A. General provisions (211.1, 211.3). Scope as above. The definitions come from 210.3.

B. Organization and personnel (211.22-211.34)

  • There "shall be a quality control unit" with authority to approve or reject:
    • components, containers, closures and in-process materials;
    • packaging, labelling and drug products, including products made under contract;
    • all procedures and specifications affecting identity, strength, quality and purity.
  • The QC unit also reviews production records (211.22).
  • Staff need education, training and experience. CGMP training must be continuing and given by qualified people (211.25).
  • Rules on clothing, hygiene and exclusion of ill staff (211.28), and records on consultants (211.34).

C. Buildings and facilities (211.42-211.58)

  • Defined areas to prevent contamination or mix-ups (211.42(c)).
  • Aseptic processing areas need, as appropriate (211.42(c)(10)):
    • smooth, cleanable surfaces;
    • temperature and humidity control;
    • HEPA-filtered air under positive pressure;
    • environmental monitoring;
    • cleaning and disinfection systems.
  • Penicillin must be made in separate facilities (211.42(d)) with completely separate air handling (211.46(d)).
  • Lighting, ventilation, plumbing and drainage, sanitation (with written procedures) and maintenance (211.44-211.58).

D. Equipment (211.63-211.72)

  • Surfaces that contact product must not be reactive, additive or absorptive (211.65).
  • Written cleaning and maintenance procedures (211.67).
  • Automated and computer systems "shall be routinely calibrated, inspected, or checked" (211.68(a)). They also need access controls, input/output checks and backup (211.68(b)).
  • Filters for injectables must not release fibres. If a fibre-releasing filter is needed, a non-fibre-releasing filter rated 0.2 micron (0.45 micron where conditions dictate) must follow it. Asbestos-containing filters are prohibited (211.72).

E. Components, containers and closures (211.80-211.94)

  • Each lot is quarantined until the QC unit samples, tests and releases it (211.82, 211.84(a)).
  • At least one identity test on each component (211.84(d)(1)). A supplier's report of analysis may replace full testing, but only with an in-house specific identity test and periodic validation of the supplier's results (211.84(d)(2)).
  • Stock rotation and retesting (211.86, 211.87).
  • Containers and closures must protect the product. Depyrogenation processes "shall be validated" (211.94).

F. Production and process controls (211.100-211.115)

  • Written procedures, approved by the QC unit, must be followed. Deviations are "recorded and justified" (211.100).
  • Each batch is formulated to give not less than 100% of the labelled active ingredient (211.101(a)).
  • Component weighing and charge-in are checked by a second person, or by one person verifying automated equipment (211.101(c)-(d)).
  • Yield calculations (211.103) and equipment identification (211.105).
  • In-process controls: weight variation, disintegration, mixing adequacy, dissolution, pH or clarity of solutions, and bioburden (211.110(a)).
  • Time limits for each production phase (211.111).
  • Microbial contamination control, including "validation of all aseptic and sterilization processes" (211.113(b)).
  • Reprocessing only with QC unit approval (211.115(b)).

G. Packaging and labelling (211.122-211.137)

  • Labels are examined on receipt and stored securely (211.122).
  • Gang-printed labelling is restricted (211.122(f)). Cut labelling requires one of four special controls (211.122(g)).
  • Labelling reconciliation, with discrepancies investigated (211.125).
  • Line clearance and lot numbering (211.130).
  • OTC products for retail sale must be in tamper-evident packaging, except dermatological, dentifrice, insulin and lozenge products. Two-piece hard gelatin capsules must also be sealed (211.132).
  • Finished-product label inspection (211.134).
  • Expiration dating based on stability testing (211.137). Exemptions apply to homeopathic products and investigational products. There is also non-enforcement for certain OTC products stable for at least 3 years (211.137(e)-(h)).

H. Holding and distribution (211.142, 211.150)

  • Quarantine until QC release, and proper storage conditions.
  • Oldest approved stock is distributed first.
  • A distribution system that allows recall.

I. Laboratory controls (211.160-211.176)

  • Scientifically sound specifications, sampling plans and test methods, plus calibration (211.160).
  • Each batch is tested against final specifications, including identity and strength of each active, before release (211.165(a)).
  • Test methods must be validated (211.165(e)).
  • A written stability programme (211.166).
  • Special testing for sterile or pyrogen-free products, ophthalmic ointments and controlled-release forms (211.167).
  • Reserve samples of at least twice the quantity needed for testing, generally kept 1 year after expiry (211.170).
  • Penicillin cross-contamination testing (211.176).

J. Records and reports (211.180-211.198)

  • Batch records are kept at least 1 year after batch expiry, or 3 years after distribution for exempt OTC products (211.180(a)).
  • An annual product quality review (211.180(e)).
  • Responsible officials are notified in writing of investigations, recalls and FDA inspection observations (211.180(f)).
  • Records required for:
    • equipment logs (211.182);
    • master production records, signed by one person and independently checked by a second (211.186);
    • batch production records (211.188);
    • laboratory records (211.194);
    • distribution records (211.196).
  • The QC unit reviews all records before release. Any unexplained discrepancy or specification failure "shall be thoroughly investigated, whether or not the batch has already been distributed", and the investigation extends to related batches (211.192).
  • Complaint handling includes a check on whether the complaint must be reported to FDA as a serious, unexpected adverse drug experience (211.198).

K. Returned and salvaged products (211.204, 211.208)

  • Returns are destroyed if their condition is doubtful, unless testing proves they meet standards.
  • Products exposed to improper storage from disasters or accidents "shall not be salvaged and returned to the marketplace" without laboratory evidence and evidence from inspection of the premises.

Under 210.1(a), the CGMP framework also includes Parts 213, 225 and 226 alongside Part 211. I did not open those parts.

Sources:

Q.02